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NF-Y Behaves as a Bifunctional
Transcription Factor That Can Stimulate
or Repress the FGF-4 Promoter
in an Enhancer-Dependent Manner
CORY T. BERNADT,*t TAMARA NOWLING,* 1 MATTHEWS. WIEBE,*t 2 AND ANGIE RIZZINO*t
*Eppley Institute for Research in Cancer and Allied Diseases, and the tDepartment of Pathology
and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-6805
NF-Y is a bifunctional transcription factor capable of activating or repressing transcription. NF-Y specifically
recognizes CCAAT box motifs present in many eukaryotic promoters. The mechanisms involved in regulating
its activity are poorly understood. Previous studies have shown that the FGF-4 promoter is regulated positively
by its CCAAT box and NF-Y in embryonal carcinoma (EC) cells where the distal enhancer of the FGF-4 gene
is active. Here, we demonstrate that the CCAAT box functions as a negative cis-regulatory element when cisregulatory elements of the FGF-4 enhancer are disrupted, or after EC cells differentiate and the FGF-4 enhancer
is inactivated. We also demonstrate that NF-Y mediates the repression of the CCAAT box and that NF-Y
associates with the endogenous FGF-4 gene in both EC cells and EC-differentiated cells. Importantly, we also
determined that the orientation and the position of the CCAAT box are critical for its role in regulating the
FGF-4 promoter. Together, these studies demonstrate that the distal enhancer of the FGF-4 gene determines
whether the CCAAT box of the FGF-4 promoter functions as a positive or a negative cis-regulatory element. In
addition, these studies are consistent with NF-Y playing an architectural role in its regulation of the FGF-4
promoter.
Key words: NF-Y; F9-differentiated cells; EC cells; Transcription; Differentiation; Enhancer;
Immunoprecipitation
transcriptional repression in the absence of hormone
(65). Upon hormone binding, the receptor undergoes
a conformational change resulting in the dissociation
of co-repressors and the recruitment of coactivators
to activate transcription. Other bifunctional transcription factors include YYl (43,81), NF-KB (90) and
NF-Y (51,62,75,89).
NF-Y is a ubiquitously expressed transcription factor that is composed of three subunits: NF-YA, NFYB, and NF-YC (also known as CBF-B, CBF-A, and
CBF-C, respectively). Each subunit contains an evolutionarily conserved HAP domain that is critical for

TRANSCRIPTIONAL regulation of gene expression
involves the proper activation and repression of specific genes. This process is controlled by sequencespecific transcription factors binding to promoters and
enhancers and interacting with co-regulators, chromatin remodeling complexes, and/or components of the
basal transcriptional machinery (34,38,65). Many transcription factors activate transcription, whereas others
repress it_ However, several transcription factors are
bifunctional and act either as activators or as repressors. Thyroid hormone receptors and retinoic acid receptors interact with a co-repressor complex to confer
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subunit interactions and DNA binding (30,45,77).
NF-YA and NF-YC each possess large glutaminerich activation domains outside of the HAP domain
(14,15,19). Located within the HAP domains of NFYB and NF-YC is a histone-fold motif that is found
in all core histones and that mediates dimerization
and contributes to DNA binding (3,4,4 7). NF-YB and
NF-YC subunits dimerize to form a complex that associates with NF-YA (77). Once the trimer forms, it
can bind specifically to CCAAT boxes, which are
cis-regulatory elements found in either orientation in
25-30% of eukaryotic promoters, and typically located between 60 and I 00 bp upstream of the transcriptional start site (11,52). Analysis of 178 NF-Ybinding CCAAT boxes demonstrated that their orientation and position relative to neighboring TATA
boxes are not distributed randomly (52). This suggests that CCAAT boxes and NF-Y may serve an
important architectural role in the organization of
promoters. In this regard, NF-Y is capable of bending
DNA 60-80° (46,72), and it has been shown to interact with components of the basal transcriptional machinery (5,16,26). Thus far, the role of NF-Y as an
architectural factor when bound to CCAAT boxes has
not been systematically tested by altering its position
or orientation.
The binding of NF-Y to gene promoters appears to
be regulated carefully during cell growth and differentiation. Although NF-Y is a ubiquitous transcription factor, it may not bind to CCAAT boxes constitutively. The binding of NF-Y to the promoter of
several cell cycle genes fluctuates during the cell cycle (12). In other cases, loss of NF-YA expression in
terminally differentiated muscle cells results in the
loss of a functional NF-Y complex (24,28). Moreover, decreased NF-YA expression has been reported
after serum deprivation of fibroblasts (13), whereas
an increase in NF-YA expression was observed during monocyte maturation (55). Although CCAAT
boxes function primarily as positive cis-regulatory elements, CCAAT boxes negatively regulate transcription in several promoters, and both the positive and
the negative effects of these CCAAT boxes are likely
to be mediated by NF-Y (9,27,29,31,39,51,75,85,89).
Importantly, NF-Y has been shown to interact with
coactivators (18,23,35,44) or co-repressors in different promoters (27,63). It remains unclear what factors
or other variables determine whether a CCAAT box
and NF-Y will activate or repress transcription of a
given gene. However, adjacent cis-regulatory elements have been shown to be required for the negative effect of CCAAT boxes (27,29).
Transcription of the fibroblast growth factor-4
(FGF-4) gene has been shown to be activated by a
CCAAT box located in its promoter approximately
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100 bp upstream of the transcription start site (41).
The FGF-4 gene is differentially expressed during
early embryogenesis (57,66), and gene targeting studies have shown that FGF-4 is essential for early development and the survival of extraembryonic tissues
(25,79,83). FGF-4 expression is restricted to cells
of the inner cell mass at the late blastocyst stage,
whereas cells of the extraembryonic endoderm, which
are derived from the inner cell mass, do not express
FGF-4 (57,66). Expression of FGF-4 is dependent on
its promoter and a powerful downstream distal enhancer located within the untranslated region of the
third and last exon (17,50). Binding motifs for known
transcription factors have been identified in both the
promoter and the enhancer. The cis-regulatory elements of the promoter include a TATA box, two GC
boxes that bind Spl and Sp3 in vitro (40,48), and an
inverted CCAAT box that binds NF-Yin vitro (41).
The cis-regulatory elements identified within the enhancer include: two high mobility group (HMG) motifs, referred to as upstream HMG (USHMG) and
downstream HMG (DSHMG), which bind Sox2 in
vitro and in vivo (49,58,87); a POU motif that binds
Oct-3 in vitro (50); and a GT box that binds Sp! and
Sp3 in vitro (48). Sox2 and Oct-3 bind cooperatively
to the DSHMG and POU motifs, respectively, to synergistically activate transcription of promoter/reporter
gene constructs (1,2,58,59,87). In addition, the coactivator p300 appears to mediate the effect of Sox2/
Oct-3 synergism (59,58), and p300 has been shown
to associate with the endogenous FGF-4 enhancer in
embryonal carcinoma (EC) cells (58).
EC cells serve as an excellent model for studying
the expression of FGF-4 during early development.
These cells are similar both biochemically and morphologically to cells of the inner cell mass (54).
Moreover, transcription of the FGF-4 gene decreases
substantially after EC cells undergo differentiation
(64,69,82,86). The downregulation of the FGF-4
gene is thought to be due, at least in part, to the decrease in Sox2 and Oct-3 that accompanies differentiation (37,42,56,60,87). To better understand the regulation of the FGF-4 gene in this model system, we
addressed four questions in this study. First, does NFy bind to the FGF-4 promoter in EC cells? Second,
if it does, does it remain associated with the FGF-4
promoter in the differentiated cells, and does it influence the FGF-4 promoter when EC cells differentiate
and transcription of the FGF-4 gene is downregulated? Third, is the function of the CCAAT box dependent on adjacent cis-regulatory elements in the
FGF-4 promoter, in particular the two upstream GC
boxes? Fourth, does the CCAAT box play an architectural role in the regulation of the FGF-4 promoter?
Our results demonstrate that NF-Y binds to the en-
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dogenous FGF-4 promoter in both F9 EC cells and
F9-differentiated cells. In addition, we show that,
upon differentiation, the FGF-4 enhancer becomes
inactive, the CCAAT box becomes a negative cisregulatory element, and NF-Y mediates the repression of the CCAAT box. Therefore, NF-Y can both
activate and repress the FGF-4 promoter, and the role
of NF-Y is dependent upon the FGF-4 enhancer.
Moreover, we show that the CCAAT box can negatively regulate transcription independent of the two
upstream GC boxes. Finally, we demonstrate that the
orientation and the position of the CCAAT box are
critical for its regulatory role in FGF-4 promoter activity. Collectively, our results address two important
issues concerning NF-Y-mediated gene regulation.
First, we demonstrate that the behavior of NF-Y and
the CCAAT box of the FGF-4 promoter is regulated
by an unexpected mechanism, specifically, by the
downstream distal enhancer of the FGF-4 gene. Second, we provide direct evidence that the position and
the orientation of the CCAAT box critically affect its
function. Thus, our data argue strongly that NF-Y can
function in an architectural manner.

MATERIALS AND METHODS
Cell Culture and Conditions

Mouse F9 EC cells were cultured on gelatinized
dishes in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (FBS, HyClone, Logan, UT) and
antibiotics, as described previously (68,70). Differentiation of F9 EC cells was induced by treatment with
5 µM retinoic acid (RA). Cells were cultured at 37°C
in a humidified atmosphere of 5% C0 2 in air.
Transient Transfection Assay

F9 EC cells were seeded at 5 x 105 cells per 100mm dish. After 24 h, the cells were transfected with
promoter/reporter gene constructs and expression vectors by the calcium phosphate precipitation method
(50). Following a 24-h incubation with the precipitate, the cells were refed with DMEM + 10% FBS.
Chloramphenicol acetyltransferase (CAT) and Pgalactosidase activities were determined 48 h after
transfection, as described previously (50). For experiments involving F9-differentiated cells, F9 EC cells
were seeded at 1 x 105 cells per 100-mm dish in
DMEM + 10% FBS and 5 µM RA and transfected
with promoter/reporter gene constructs and expression vectors 72 h later. Following a 24-h incubation
with the precipitate, the cells were refed with DMEM
+ 10% FBS and 5 µM RA. CAT and P-galactosidase
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act1V1t1es were determined 72 h after transfection.
Molar amounts of DNA were kept constant with the
addition of null plasmid DNA, pCMV5. All transfections were normalized by addition of 1 µg of CMVPgalactosidase (Clontech, Palo Alto, CA). All transfections were performed in duplicate. Error bars indicate
the SD of either the fold induction or the relative
CAT activity obtained by the compilation of multiple
experiments as indicated in the figure legends. Data
were evaluated for statistical significance using the
Student's t-test.
Plamid Constructs

The following promoter/reporter constructs have
been described elsewhere: 427T+E (also known as
pKFGF427T+E) (48,73), 427T, CCAATmut+E (also
known as -427T+E CCAATmut), CCAATmut (also
known as -427T CCAATmut) (36), TKCat, TKCat+E,
427T+EnGSp, GCmut (also known as 427T SplDPE), CCAATmut+EnGSp (also known as 427TCmut
+EnGSp) (58), and GCmut+E (also known as SplDP)
(48). GCmut/CCAATmut contains mutations in both
the GC boxes and the CCAAT box of the FGF-4
promoter but lacks the enhancer and was constructed
by removing the enhancer from 427TGC/Cmut+
EnGSp (58) by digestion and religation of the Sad
sites flanking the enhancer. CCAATmut+EGTmut
and CCAATmut+EHMGmut were constructed by isolating the enhancers from Sp IE (48) and 427T+
DSHMGmut (49), respectively, by digestion with
Sad and ligating them into the Sacl site of CCAATmut. 427TG4/CCAAT was constructed using PCR
with 427T as the template and the following primers:
upper primer, 5'-CCTCggatccGGAGGACAGTCC
ACCGACCTGCGCCCCGGCTCCCAGG-3'; lowef
primer, 5'-TCACCGggatccGAGGAGGCGCGGGCcZ
GGGCGGTGGC-3'. Lower case sequence denote!;
BamHI sites, sequence in bold denotes the Gal4 binding site, and the underlined sequence is wild-typ~
promoter sequence. This PCR amplified the entir~
plasmid except for the CCAAT box, which was re~
placed by the Gal4 binding site. The BamHI sites
were then used to circularize the plasmid. Upstream
CCAAT+E, reversed CCAAT+E, upstream CCAATI,
I
and reversed CCAAT were generated by the Quick[
Change method of mutagenesis (Stratagene, La Jolla;
CA) using the promoter/reporter constructs CCAAT
mut+E and CCAATmut, respectively. The following
primer and its complement were used to replac~
sequence upstream of the two GC boxes with ~
CCAAT box in the constructs upstream CCAAT+~
and upstream CCAAT: 5'-CAGCTCAAGTCAGTGK
TTGGCAGAGCAGAAAGGTTCTGGCGG-3'. Th~
sequence in bold denotes the CCAAT box. The folf
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lowing primer and its complement were used to create a CCAAT box in the opposite orientation of the
original CCAAT box in the constructs reversed
CCAAT+E and reversed CCAAT: 5'-GCGCCTCCT
CCCCCGGTGCTGCCAATCACGCGACCTGC-3'.
The sequence in bold denotes the inverted CCAAT
box.
The following expression plasmids were utilized:
CMVGal4 and Gal4/Sox2 121-319 (59); the SV40Gal4 fusion vector, pM3 (74); Gal4/p300 1-2414
(full-length p300 fused to the DNA binding domain
of the yeast transcription factor Gal4) and Gal4/p300
964-1922 (p300 amino acids 964-1922 fused to the
DNA binding domain of Gal4) (88); pNF-YA29 (53);
and pSG424-NF-YC Lil, which was received from
Keiko Funa (Goteborg University) (32). CMVGal4/
NF-YA 1-261 was generated by amplifying amino
acids 1-261 of NF-YA and inserting the amplified
fragment into the HindIII site of CMVGal4 using the
following primers: upper primer, 5' -AGCTaagcttAT
GGAGCAGTATACGACAAACAGC-3'; lower primer,
5 '-AGCTaagcttCTCTTCTTCCAGCATCTCTGCTC
CAG-3'. The lowercase sequences denote HindIII
sites. CMVGal4/NF-YB Li50-139 was made in two
steps. The first step involved. amplifying the entire
NF-YB sequence and inserting it into the BamHI site
of CMVGal4 to create CMVGal4/NF-YB using the
following primers: upper primer, 5'-CTACGTggatcc
T ATGACAATGGACGGCGACAG-3'; lower primer,
5'-CGAACTggatccTCATGAAAACTGAATTTGCTG3'. The lowercase sequences denote BamHI sites. The
second step involved amplifying the entire CMVGal4/NF-YB sequence except for the sequence that
encodes amino acids 50 to 139 of NF-YB. The following primers used for this step inserted a KpnI site
to allow the amplified plasmid to be religated: upper
primer, 5'-CCTCggtaccAAGTTCAGAGAGGCCAT
GAAAG-3'; lower primer, 5'-CCTCggtaccACTTTC
TTTTGAACCATTTG-3'. The lowercase sequences
denote Kpnl sites.
Chromatin Immunoprecipitation (Ch!P)

ChIP was performed as follows. On day 1, F9 EC
5
cells were seeded at a density of 2 x 10 on 100-mm
dishes and induced to differentiate with 5 µM RA.
On day 4, F9 EC cells were seeded at 2 x 106 cells
per 100-mm dish. On day 5, cross-linking was performed by addition of formaldehyde to the culture
medium at a final concentration of 1% for 10 min at
room temperature. Cells were then washed and scraped
into PBS containing 1 mM PMSF, 1 µg/ml aprotinin,
and 1 µg/ml pepstatin A. Cells were lysed in SOS
lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris,

'

' BERNADT ET AL.

pH 8.1) containing 1 mM PMSF, 1 µg/ml aprotinin,
and 1 µg/ml pepstatin A by adding 200 µl of lysis
buffer per 1 x 106 cells. Following incubation on ice
for 1O min, the DNA was sheared to lengths between
200 and 1000 bp by sonication, and cell debris was
pelleted. Aliquots (200 µl) of the sonicated cell supernatant were diluted IO-fold by the addition of
ChIP dilution buffer (0.01 % SDS, 1.1 % Triton X100, 1.2 mM EDTA, 16.7 mM Tris-HCI, pH 8.1, 167
mM NaCl) plus 1 mM PMSF, 1 µg/ml aprotinin, and
l µg/ml pepstatin A. To reduce nonspecific background, the samples were precleared with 80 µl of
salmon sperm DNA/protein A agarose (50% slurry)
(Upstate Biotechnology, Lake Placid, NY) for 30 min
at 4 °C with rotation. The precleared samples were
then incubated with 15 µg NF-YA antibody (H-209;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 15
µg NF-YB antibody (FL-207; Santa Cruz Biotechnology, Inc.), or 15 µg preimmune normal rabbit IgG
(Santa Cruz Biotechnology, Inc.) at 4 °C with rotation
overnight. Immune complexes were collected with 60
µl of salmon sperm DNA/protein A agarose (50%
slurry) for 1 h at 4°C with rotation. The samples were
washed once with low-salt wash buffer (0.1 % SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl,
pH 8.1, 150 mM NaCl), high-salt buffer (0.1 % SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl,
pH 8.1, 500 mM NaCl), and LiCl wash buffer (2.25
M Li Cl, 1% IGEPAL-CA630, 1% deoxycholic acid,
1 mM EDTA, 10 mM Tris, pH 8.1) and twice with
TE buffer (10 mM Tris-HCI, 1 mM EDTA, pH 8.0).
Complexes were eluted by two incubations with 250
µl of elution buffer (1 % SOS, 0.1 M NaHC0 3) at
room temperature for 10 min with rotation. NaCl was
added to a final concentration of 0.2 M, and the samples were incubated at 65°C for 4 h to reverse the
cross-links. The samples were treated with 20 µg of
Proteinase K for 1 h at 45°C after the addition of 10
µl 0.5 M EDTA and 20 µl 1 M Tris-HCI, pH 6.5.
DNA was purified using the GeneClean turbo kit (Q
Biogene, Carlsbad, CA) following the manufacturer's
directions. In studies not shown, ChIP analysis was
performed with HDACl antibodies (H-51, Santa Cruz
Biotechnology).
The following primer pairs were used to detect the
presence of DNA fragments containing the indicated
regions. FGF-4 promoter: FGFproU2, 5'-GTAAGG
AAGGAGCACAGGAGAT-3' and FGFproL3, 5'CAGACCTAAGTAGCGAGAGCAA. Tf3R-II promoter: T~RIIpro U, 5' -ACACCACTTTCGAGCTTG
TTTTGC and Tf3RIIproL, 5'-CGCGAGTGACTCA
CTCATCAAC. FGF-4 5' region: FGF5'U, 5'-ACCT
CACCTGTGCCCTGTTGAAT-3' and FGF5'L, 5'GTGCTCATCTCCCCAGACTGTTTCT-3'. PCR was
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performed on equivalent volumes of each sample and
analyzed at multiple cycles. Results are presented for
one cycle.

RESULTS
The FGF-4 Enhancer ls Inactive
and the FGF-4 Promoter Can Be Activated
in F9-Differentiated Cells

The transcription of the FGF-4 gene depends on a
powerful distal enhancer located 3 kb downstream of
the transcription start site. In F9 EC cells, the FGF4 enhancer increases the activity of FGF-4 promoter/
reporter gene constructs over 50-fold (17,50). Previous studies demonstrated that the activity of FGF-4
promoter/reporter gene constructs is greatly reduced
after differentiation. Although the FGF-4 enhancer
appears to be inactivated after EC cells differentiate
(17,50), it was unclear whether the enhancer is completely inactivated after differentiation and whether
differentiation influences the function of the FGF-4
promoter. To address the first issue, we tested the
effect of the 316 bp FGF-4 enhancer on the heterologous herpes simplex virus thymidine kinase (TK)
promoter. We chose the TK promoter because it is
active in F9-differentiated cells, and because this promoter is stimulated five- to sixfold by the FGF-4 enhancer in F9 EC cells (58). Here we show that the
FGF-4 enhancer hardly affected the TK promoter in
F9-differentiated cells (Fig. IA). This argues that the
FGF-4 enhancer exhibits little or no activity after EC
cells differentiate. To determine whether differentiation influences the function of the FGF-4 promoter,
we initially tested whether the FGF-4 promoter can
be activated in F9-differentiated cells. For this purpose, we examined whether the activation domains of
Sox2 and p300 could stimulate the FGF-4 promoter
in F9-differentiated cells, because both factors have
been shown to activate the FGF-4 promoter (37,58,
87). For these studies, we utilized the promoter/reporter gene construct 427T+EnGSp, in which the
CAT reporter gene is under the control of the FGF-4
promoter and a modified FGF-4 enhancer (58). More
specifically, in this construct the DSHMG and POU
motifs of the enhancer have been replaced by a Gal4
DNA binding site, allowing Gal4-chimeric fusion
proteins to bind to the FGF-4 enhancer. Cotransfection of 427T+EnGSp with an expression plasmid for
Gal4/Sox2 or Gal4/p300 resulted in over a 150-fold
induction in reporter gene activity in F9-differentatiated cells (Fig. 1B and C, respectively). This is similar to the 150-fold induction that is observed with
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Gal4/Sox2 in F9 EC cells (Fig. ID). These results
demonstrate that the FGF-4 promoter can be activated to comparable levels in both F9 EC and F9differentiated cells. Therefore, inactivation of the
FGF-4 gene in F9-differentiated cells appears to be
due primarily to loss of enhancer function and does
not appear to be due to an FGF-4 promoter that is
irreversibly repressed.
The CCAAT Box of the FGF-4 Promoter
Can Function as a Positive or a Negative
cis-Regulatory Element

Several cis-regulatory elements have been identified in the FGF-4 promoter, including an inverted
CCAAT box and a pair of GC boxes (41,48). Previous studies have shown that disruption of the CCAAT
box and the GC boxes in FGF-4 promoter/reporter
gene constructs lowers reporter gene activity when
these constructs and their wild-type counterparts are
compared in F9 EC cells. In the case of the CCAAT
box, its disruption can reduce FGF-4 promoter activity as much as 70% (41,48). Surprisingly, in F9differentiated cells, disruption of the CCAAT box resulted in a twofold increase in reporter gene activity
relative to a construct with a wild-type promoter (Fig.
2A). This finding suggests that the CCAAT box functions as a negative cis-regulatory element in F9differentiated cells. Because the FGF-4 enhancer is
inactivated in F9-differentiated cells, we examined
the effect of disrupting the CCAAT box in F9 EC
cells utilizing promoter/reporter gene constructs that
do not contain the FGF-4 enhancer. In this context,
disruption of the CCAAT box resulted in a four- to
fivefold increase in reporter gene activity (Fig. 2B).
This observation argues that the CCAAT box functions as a negative regulatory element in the absence
of the FGF-4 enhancer. This property is unique to
the CCAAT box, because disruption of the two GC
boxes (GCmut) resulted in a decrease in promoter activity when the FGF-4 enhancer was not present (Fig.
2B). Moreover, the ability of the CCAAT box to
function negatively in the absence of the enhancer
was not impaired when the two GC boxes were disrupted. This was illustrated by the increase in activity
of the construct in which both the CCAAT box and
the two GC boxes were disrupted (GCmut/CCAATmut) relative to the construct in which only the two
GC boxes had been disrupted (GCmut) (Fig. 2B). Importantly, our studies indicate that disruption of the
CCAAT box did not create a sequence for a positive
acting factor. In this regard, similar results were obtained when a different DNA sequence was used to
disrupt the CCAAT box (data not shown). Moreover,
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Figure I. The FGF-4 enhancer is inactive and the FGF-4 promoter can be activated in F9 differentiated cells. (A) Transfection of F9differentiated cells with 15 µg of TKCat or TKCat+E. Results are presented as CAT expression relative to the activity of TKCat, which was
set to 1. This experiment was performed three times. The data shown are the compilation of the three experiments, and the standard deviation
for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activity of TKCat+E was not
significantly different than the activity of TKCat. (B) Transfection of F9-differentiated cells with 15 µg of 427T+EnGSp alone or with I µg
of a vector expressing Gal4 or Gal4/Sox2. Results are presented as fold induction over the activity of 427T+EnGSp alone, which was set
to I . This experiment was performed two times. The data shown ate the compilation of the two experiments, and the standard deviation for
each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activation by Gal4/Sox2 was
significant with a p-value of Jess than 0.05. (C) Transfection of F9-differentiated cells with 15 µg of 427T+EnGSp alone or with 5 µg of a
vector expressing Gal4 or Gal4/p300. Results are presented as fold induction over the activity of 427T+EnGSp alone, which was set to I.
This experiment was performed three times. The data shown are the compilation of the three experiments, and the standard deviation for
each condition is represented by error bars. Analysis of the data by the Student's I-test indicated that the activation by Gal4/p300 was
significant with a p-value of less than 0.05. (D) Transfection of F9 EC cells with 15 µg of 427T+EnGSp alone or with 5 µg of a vector
expressing Gal4 or Gal4/Sox2. Results are presented as fold induction over the activity of 427T+EnGSp alone, which was set to I. This
experiment was performed five times. The data shown are the compilation of the five experiments, and the standard deviation for each
condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activation by Ga14/Sox2 was significant
with a p-value of less than 0.05.

although the CCAAT box motif of the FGF-4 promoter has been shown to bind NF-Y in vitro (41), no
DNA/protein complexes formed in a gel electrophoretic mobility shift assay in which the DNA probe
contained the mutant CCAAT box sequence (data not
shown). Collectively, these results argue that the
CCAAT box of the FGF-4 promoter can function
both as a positive and a negative cis-regulatory element, and that the function of the CCAAT box is
dependent upon the activity of the FGF-4 enhancer.
Several important cis-regulatory elements have

been identified in the FGF-4 enhancer, including two
HMG motifs that bind Sox2, a POU motif that binds
Oct-3, and a GT box that binds Spl and Sp3 (40,4850,87). Moreover, several studies have shown that at
least two of the cis-regulatory elements of the FGF4 enhancer work together to cooperatively activate
the FGF-4 promoter (1,2,49,59,87). To determine
which of these cis-regulatory elements influence the
function of the CCAAT box in F9 EC cells, we utilized promoter/reporter gene constructs in which the
different cis-regulatory elements of the enhancer
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Figure 2. The FGF-4 CCAAT box functions as a negative cis-regulatory element in the absence of a functional enhancer. (A) Transfection
of F9-differentiated cells with 15 µg of 427T+E or CCAATmut+E. Results are presented as fold induction over the activity of 427T+E,
which was set to 1. This experiment was performed four times. The data shown are the compilation of the four experiments, and the standard
deviation for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activity of
CCAATmut+E was significantly greater than the activity of 427T+E with a p-value of less than 0.05. (A) Transfection of F9 EC cells with
15 µg of 427T, CCAATmut, GCmut, or GCmut!CCAA Tmut. Results are presented as fold induction over the activity of 427T, which was
set to 1. The fivefold increase indicates fold induction of CCAATmut relative to 427T, and the fourfold increase indicates fold induction of
GC/CCAATmut relative to GCmut. This experiment was performed three times. The data shown are the compilation of the three experiments,
and the standard deviation for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the
activity of CCAATmut was significantly greater than the activity of 427T with a p-value of less than 0.05, and the activity of GCmut/
CCAATmut was significantly greater than the activity of GCmut with a p-value of less than 0.05.

were disrupted along with the CCAAT box. The activities of these constructs were compared to constructs that contain a wild-type CCAAT box. Disruption of the CCAAT box in conjunction with the GT
box, the DSHMG motif, or both the DSHMG and
POU motifs each resulted in a two- to threefold increase in reporter gene activity in F9 EC cells (Fig.

3). Although this is less than the four- to fivefold increase that is observed when the entire enhancer is
absent, these findings argue that the GT box, the
DSHMG motif, and the POU motif of the FGF-4 enhancer are required for the CCAAT box to function
positively. Moreover, these findings argue that disruption of any of these cis-regulatory elements in the
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enhancer is sufficient to convert the CCAAT box of
the FGF-4 promoter from a positive to a negative cisregulatory element. Interestingly, disruption of the
CCAAT box in conjunction with the USHMG motif
did not lead to an increase in reporter gene activity
(data not shown). Thus, although the USHMG site
contributes to the function of the FGF-4 enhancer
(49), the USHMG site does not appear to influence
the inhibitory behavior of the CCAAT box.

The Coactivator p300 Converts the FGF-4
CCAAT Box From a Negative to a Positive
cis-Regulatory Element
The transcription factors Sox2 and Oct-3 bind cooperatively to the DSHMG and POU motifs of the
FGF-4 enhancer to synergistically activate transcription (1,59,87), and p300 appears to mediate this synergism (58,59). In addition, p300 can physically interact with NF-Y in other promoters (23,44). These
findings led us to test directly the effect of p300 on
the function of the FGF-4 CCAAT box. For these
studies, we employed the promoter/reporter gene

construct 427T+EnGSp, which was described above,
and the construct CCAATmut+EnGSp in which the
CCAAT box of 427T+EnGSp has been disrupted.
Cotransfection of F9 EC cells with CCAATmut+
EnGSp plus an expression plasmid for Gal4/p300 resulted in 50% less reporter gene activity relative to
the activation induced by Gal4/p300 with the construct that contains a wild-type CCAAT box (Fig.
4A). Importantly, previous studies demonstrated that
Gal4/p300 activates the activity of 427T+EnGSp, but
does not influence the activity of the parent construct,
427T+E, which lacks a binding site for the yeast transcription factor Gal4 (58). Therefore, the CCAAT
box functions as a positive cis-regulatory element in
response to p300, as well as the FGF-4 enhancer. It
should be noted that the difference in the activity induced by Gal4/p300 in F9 EC cells (approximately
25-fold) (Fig. 4A) relative to the activity that is induced by Gal4/p300 in F9-differentiated cells (approximately 150-fold) (Fig. IC) may be due to different expression levels of Gal4/p300 or to differential
posttranslational modifications of p300. In this regard, the levels of p300 and its associated histone
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acetyltransferase activity have been reported to change
after F9 EC cells undergo differentiation (10,61). To
extend these findings, we examined whether the ability of the FGF-4 CCAAT box to function positively
is specific for the FGF-4 enhancer. For this purpose,
the FGF-4 enhancer of 427T+E was replaced with
the heterologous SV40 enhancer to generate 427T+

SV40E. In F9 EC cells, the activities of 427T+E and
427T+SV40E were similar (data not shown). We
chose the SV40 enhancer because it has been shown
to mediate its effect, at least in part, through p300
(21). Moreover, unlike the FGF-4 enhancer, the activity of the SV40 enhancer increases with differentiation (78). In the presence of the SV40 enhancer, dis-
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ruption of the CCAAT box results in a decrease in
reporter gene activity in both F9 EC and F9-differentiatcd cells (Fig. 4B). Similar to the FGF-4 enhancer,
the SV40 enhancer enables the CCAAT box to function as a positive cis-regulatory element. Together,
these findings demonstrate that p300 is not only capable of activating the FGF-4 promoter, but it is also
able to convert the FGF-4 CCAAT box from a negative to a positive cis-rcgulatory element.
NF-Y Mediates the Repression
of the FGF-4 CCMT Box

Previous studies have shown NF-Y can bind to the
FGF-4 CCAAT box sequence in vitro when nuclear

extracts from F9 EC and F9-differentiated cells were
examined by electrophoretic mobility shift assays
(41 ). Moreover, functional studies utilizing a dominant negative form of NF-YA, NF-YA29, have shown
NF-Y regulates FGF-4 promoter activity positively
in F9 EC cells (41 ). NF-Y A29 contains a mutation in
the DNA binding domain of NF-YA that allows NFy A29 to bind to the NF-YB-NF-YC dimer, but prohibits the trimeric complex from binding to DNA
(S3). Ectopic expression of NF-Y A29 in F9 EC cells
reduces the activity of the promoter/reporter gene
construct 427T+E by as much as 70% (41). In the
current study, we used NF-YA29 to examine whether
NF-Y represses the FGF-4 promoter in the absence
of the FGF-4 enhancer. Cotransfection ofF9 EC cells
with 427T and increasing amounts of NF-Y A29 resulted in a dose-dependent increase in reporter gene
activity (Fig. SA). In addition, we tested the effect of
NF-YA29 on 427T+E in F9-differentiated cells,
where the FGF-4 enhancer is inactive. Again, increasing amounts of NF-YA29 led to a dose-dependent increase in reporter gene activity (Fig. SB).
Moreover, NF-YA29 had no effect on the FGF-4
promoter/reporter construct in which the CCAAT box
was disrupted. Together, these findings argue NF-Y
is functionally involved in the repression of the FGF4 promoter in the absence of an active enhancer.
To extend these studies, ChlP analyses were performed to determine whether NF-Y is bound to the
endogenous FGF-4 promoter before and after F9 EC
cells differentiate. For this purpose, antibodies specific for NF-YA and NF-YB were used. We determined that both NF-Y antibodies immunoprecipitated
chromatin fragments containing the FGF-4 gene promoter from F9 EC cells, as well as from F9-differentiated cells (Fig. SC). As a control, we demonstrated
that NF-Y antibodies did not immunoprecipitate
chromatin fragments from a region of the genome 3
kb upstream of the FGF-4 promoter. To help confirm
these studies, we examined the in vivo binding of
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NF-Y to the promoter of the type II transforming
growth factor-13 receptor (Tl3R-II) gene in both F9
EC and F9-differentiated cells. The Tl3R-II promoter
was used as a positive control, because NF-Y has
been shown to positively regulate this promoter in
F9-differentiated cells (6). Together, the functional
studies with NF-YA29 and the ChIP analyses suggest
that NF-Y binds to and activates the FGF-4 promoter
in the presence of a functional enhancer, whereas in
the absence of a functional enhancer, NF- Y binds to
and represses the FGF-4 promoter. Currently, it is
unclear how NF-Y represses the FGF-4 promoter.
Recent studies argue that NF-Y can interact with the
co-repressor, histone deacetylase 1 (HDACJ), and
repress two other promoters (63,75). To examine
whether this was the case for NF-Y and the FGF-4
promoter, we performed ChIP analysis with an HDAC!
antibody. However, in F9-differentiated cells, we did
not observe enrichment of the FGF-4 promoter with
antibodies that recognize HDACl (data not shown).
Although NF-Y has been reported to repress transcription from several promoters (27,51,63, 7S,89), no
studies have mapped the region(s) of NF-Y responsible for repression. The transactivation domains of
NF-Y have been mapped to glutamine-rich regions of
NF-YA and NF-YC (14,lS,19). When isolated and
fused to heterologous DNA binding domains, such as
LexA and Ga14, these domains can activate transcription. We used a similar approach to examine whether
the individual subunits of NF-Y can mediate FGF-4
promoter repression. For these studies, the promoter/
reporter gene construct 427T was modified to include
a Gal4 DNA binding site in place of the CCAAT
box in the FGF-4 promoter (427TG4/CCAAT). This
modification allows Gal4/NF-Y fusion proteins to
bind to the FGF-4 promoter. The HAP domain of
each of the NF-Y subunits was removed from the
Gal4/NF-Y expression plasmids used in this study
(Gal4/NF-YA 1-261, Gal4/NF-YC ~l and Gal4/NFYB .1.S0-139) (Fig. 6A), because these domains are
involved in subunit interactions and DNA binding
(30,45,77). Cotransfection of F9 EC cells with
427TG4/CCAAT and increasing amounts of an expression plasmid for Gal4/NF-Y A 1-261 or Gal4/
NF-YC .1.1 generated a dose-dependent increase in
reporter gene activity (Fig. 6B and C, respectively).
In contrast, expression of Gal4/NF-YB ~S0-139 appears to inhibit reporter gene activity (Fig. 6D). However, the decrease in activity is similar to the decrease
that is observed with an expression plasmid for the
Ga14 DNA binding domain alone. This result is most
likely a reflection of the very weak activation potential of Gal4/NF-YB (lS,32). In this regard, when F9
EC cells were cotransfected with Gal4/NF-YB .1.S0139 and the promoter/reporter gene construct 427T+
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Results are presented as CAT expression relative to the activity of 427TG4/CCAAT, which was set to 1. This experiment was performed
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error bars. Analysis of the data by the Student's t-test indicated that the decrease in CAT activity observed by the transfection of 2 µg of
Gal4/NF-YB Ll.50-139 was not significantly different than the decrease in CAT activity observed by the transfection of 2 µg of Gal4.
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EnGSp, which contains a Gal4 DNA binding site inserted into the FGF-4 enhancer, Gal4/NF-YB ~50139 induced a small increase (approximately four- to
fivefold) in reporter gene activity, whereas Gal4/NFYA 1-261 and Gal4/NF-YC ~1 induced approximately 15- and 50-fold increases in reporter gene activity, respectively (data not shown). Together, these
results argue that the individual subunits of NF-Y are
not sufficient to repress FGF-4 promoter activity.

The Orientation and the Position Are Important
for CCAAT Box Function
Because none of the three subunits of NF-Y appeared to repress the FGF-4 promoter on their own
and all three subunits are required for binding to
DNA, we considered the possibility that repression
by NF-Y may be architectural in nature. In this regard, analysis of bona fide NF-Y binding CCAAT
boxes demonstrated that CCAAT boxes of TATAcontaining promoters are most often located between
80 and 100 bp upstream of the transcription start site
(52). In addition, NF-Y has been shown to bend DNA
60-80° (46,72). To determine whether the orientation
and/or the position of the CCAAT box in the FGF-4
promoter influence its function, we generated a set of
promoter/reporter gene constructs in which the wildtype CCAAT box sequence was replaced with a
CCAAT box of the opposite orientation (reversed
CCAAT +E and reversed CCAAT) (Fig. 7A). In another set of promoter/reporter gene constructs, the
CCAAT box sequence was moved from its wild-type
position (-101 to - ll 1) to an upstream position
(-306 to -296) within the FGF-4 promoter (upstream
CCAAT+E and upstream CCAAT). The sequence
used to change the orientation and the position of the
CCAAT box consisted of 11 nucleotides that included the CCAAT pentanucleotide plus three 5'- and
three 3'-flanking bp. These 11 bp constitute an NF-Y
consensus site that has been derived from both functional and statistical studies (7,52). These promoter/
reporter gene constructs were tested in F9 EC cells
to examine the effect of the orientation and the position on the function of the CCAAT box in both the ;-.
presence and the absence of the FGF-4 enhancer. In
the presence of the FGF-4 enhancer, reversing the
orientation of the CCAAT box resulted in reporter
gene activity similar to that of the wild-type promoter/reporter gene construct (Fig. 7B). In contrast,
moving the CCAAT box to an upstream site led to a
decrease in reporter gene activity, to levels similar to
those with CCAATmut+E. Therefore, when the FGF4 enhancer is present, the FGF-4 CCAAT box can
function in either orientation to positively affect promoter activity. In direct contrast, when the FGF-4
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enhancer is absent, either reversing the orientation of
the CCAAT box or moving the CCAAT box upstream neutralized its ability to repress the FGF-4
promoter (Fig. 7C). Therefore, both the orientation
and the position of the CCAAT box are important
for the CCAAT box to function as a negative cisregulatory element in the absence of the FGF-4 enhancer. Collectively these results demonstrate that
both the orientation and the position of the CCAAT
box influence its ability to properly regulate the FGF4 promoter and argue for an architectural role by the
CCAAT box in FGF-4 promoter repression.

DISCUSSION
The work described in this study demonstrates that
the CCAAT box of the FGF-4 promoter can function
as a positive cis-regulatory element in the presence
of an active FGF-4 enhancer or function as a negative cis-regulatory element when the FGF-4 enhancer
is inactive. Previous studies have shown that NF-Y
mediates the positive effect of the CCAAT box of the
FGF-4 promoter in F9 EC cells (41). In this study,
we demonstrate that NF-Y mediates the repressive effect of this CCAAT box and that the status of the
FGF-4 enhancer determines whether NF-Y activates
or represses the FGF-4 promoter. In addition, we show
that NF-Y associates with the endogenous FGF-4 promoter in both F9 EC cells and F9-differentiated cells.
Studies to determine how NF-Y mediates repression
demonstrate that the individual subunits of NF-Y are
not sufficient for repression, and that the orientation
and the position of the CCAAT box are important for
its ability to repress the FGF-4 promoter.
Differentiation of EC cells results in the downregulation of FGF-4 transcription (64,69,82,86). Although previous studies have suggested that the FGF4 enhancer is inactivated after EC cells differentiate
(17,50), it was unclear whether the enhancer is completely inactivated after differentiation or whether the
function of the FGF-4 promoter is actively repressed
after differentiation. We demonstrate here that the
FGF-4 enhancer is incapable of activating the heterologous TK promoter in F9-differentiated cells. The
most likely explanation for the loss of FGF-4 enhancer activity is the loss of Sox2 and Oct-3 expression that occurs with differentiation (56,87). In this
regard, Sox2 and Oct-3 bind cooperatively to the DSHMG and POU motifs to synergistically activate
transcription of the FGF-4 gene (1,2,59,87), and both
Sox2 and Oct-3 mRNA are nearly undetectable 72 h
after EC cells have been induced to differentiate
(56,87). Unlike Sox2 and Oct-3, the transcription factors NF-Y, Spl, and Sp3 that bind to the FGF-4 pro-

BERNADT ET AL.

206
A

US

HMG

CCAAT TATA

I

i

I

OS

HMG POU

I

I

GT

I

427T+E
CCAATmut+E
ReversedCCAAT+E
UpstreamCCAAT+E
427T
CCAATmut
ReversedCCAAT
UpstreamCCAAT

B

.::·
·;::

1.2

-

1.0

-

<"'
~

0.8

-

0.6

-

=..."'"'

0.4

-

0.2

-

=

u

Q)

i:=:

T
T

'

,

'

0.0

T
'

427T+E

CCAATmut+E

Reversed
CCAAT+E

Upstream
CCAAT+E

427T

CCAATmut

Reversed
CCAAT

Upstream
CCAAT

c
5.0
4.0

=

~

"'

:;;

-=

3.0

"'C

"'C

0

2.0

~

1.0
0.0

Figure 7. The orientation and the position of the CCAAT box is important for the regulation of the FGF-4 promoter. (A) Physical map of
the promoter/reporter gene constructs that contain a reversed or upstream CCAAT box. (B) Transfection of F9 EC cells with 15 µg of
427T+E, CCAATmut+E, invert CCAAT+E, and upstream CCAAT+E. Results are presented as CAT expression relative to the activity
of 427T+E, which was set to I. This experiment was performed five times. The data shown are the compilation of the five experiments,
and the standard deviation for each condition is represented by error bars. Analysis of the data by the Student's 1-test indicated that the
activity of CCAATmut+E and upstream CCAATmut+E was significantly less than the activity of 427T+E with a p-value of less than 0.05,
whereas the activity of reversed CCAAT+E was not significantly different than the activity of 427T+E. (C) Transfection of F9 EC cells
with 15 µg of 427T, CCAATmut, invert CCAAT and upstream CCAAT. Results are presented as fold induction over the activity of 427T,
which was set to I. This experiment was performed four times. The data shown are the compilation of the four experiments, and the standard
deviation for each condition is represented by error bars. Analysis of the data by the Student's 1-test indicated that the activity of CCAATmut,
reversed CCAATmut, and upstream CCAATmut were significantly greater than the activity of 427T with a p-value of less than 0.05.
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mater are expressed before and after EC cells differentiate and differentiation does not significantly alter
their binding to DNA in vitro (41,42).
Examination of the FGF-4 promoter led to the surprising finding that the promoter is subject to repression in the absence of a functional FGF-4 enhancer.
More specifically, we show that disruption of the
CCAAT box results in an increase in FGF-4 promoter activity in F9 EC cells in the absence of the
FGF-4 enhancer and in F9-differentiated cells where
the FGF-4 enhancer is inactive. The increased FGF4 promoter activity (four- to fivefold) that is observed
when the CCAAT box is disrupted in F9 EC cells,
relative to the increase that is observed in differentiated cells (twofold) where the enhancer is inactive, is
most likely the result of other changes that occur
within the promoter after differentiation. Moreover,
it appears that the GC boxes are not involved in the
repression of the FGF-4 promoter, and the GC boxes
are not required by the CCAAT box to mediate repression. These latter findings are of particular interest, because neighboring cis-regulatory elements are
involved with CCAAT boxes in the repression of
other promoters. Specifically, the CCAAT box of the
RUSH/SMARCA3 promoter is only repressive in
conjunction with two upstream Spl sites (29), while
the CCAA T box of the growth hormone receptor promoter is involved in the recruitment of a "repressosome" complex that involves several neighboring cisregulatory elements (27).
Like the CCAAT box of the FGF-4 promoter, the
CCAAT boxes of several cell cycle-dependent promoters also function in a context-dependent manner.
Cyclin Bl, B2, cdc25, and cdc2 are all required for
progression through the G2 phase of the cell cycle.
The promoters of these genes contain CCAAT boxes
that positively modulate their activity through the
progression of the cell cycle (8,24,80,91). However,
during p53-induced G 2 arrest, the CCAAT boxes of
these promoters negatively regulate the transcription
of these genes (51,89). Therefore the regulation of
the cyclin Bl, B2, cdc25, and cdc2 promoters by the
CCAAT box is dependent upon the cell cycle. However, the mechanism involved remains to be determined. Our studies indicate that the regulation of the
FGF-4 promoter by the CCAAT box is dependent
upon the FGF-4 enhancer, which is located more
than 3 kb downstream from the FGF-4 promoter
CCAAT box. Furthermore, our results demonstrate
that disruption of the DSHMG motif, the DSHMG
and POU motifs, or the GT box in the enhancer is
sufficient to convert the CCAAT box from a positive
to a negative cis-regulatory element. The effects of
disrupting the DSHMG and POU motifs are particularly interesting, because Sox2 and Oct-3 synergisti-
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cally activate transcription by binding to these cisregulatory elements in the FGF-4 enhancer (1,59,87).
Moreover, p300 has been shown to mediate the effects of Sox2 and Oct-3 on gene transcription (58,
59), and p300 is associated with the endogenous
FGF-4 enhancer in F9 EC cells (58). This led us to
examine the effect of p300 on the function of the
CCAAT box by physically tethering p300 to the disabled FGF-4 enhancer in 427T+EnGSp. Our results
demonstrate that p300 can convert the CCAAT box
in the disabled FGF-4 enhancer from a negative to a
positive cis-regulatory element. Together, our findings argue that the FGF-4 enhancer strongly influences the behavior of the CCAAT box and further
suggest that p300 is likely to mediate, at least in part,
the positive influence of the FGF-4 enhancer on the
promoter CCAAT box.
Previous work utilizing the dominant negative NFy A29 has shown that NF-Y is functionally involved
in the activation of the FGF-4 promoter (41). In this
study, NF-YA29 was used to demonstrate that NF-Y
can function to repress the FGF-4 promoter when the
FGF-4 enhancer is either absent or inactive. NFy A29 has been utilized by others to show that NF-Y
mediates the repression of certain cell cycle-dependent promoters during p53-induced G2 arrest and the
repression of the growth hormone receptor promoter
(27,51,89). NF-Y is one of several bifunctional transcription factors that include the nonsteroidal nuclear
receptors, YYl and NF-KB. The context of bifunctional transcription factors dictates whether they activate or repress transcription. NF-Y functions as a bifunctional transcription factor in the regulation of
several cell cycle-dependent promoters. In the case of
the von Willebrand factor promoter, NF-Y binds to
the canonical CCAAT box of the von Wille brand factor promoter in endothelial cells to activate transcription, whereas in nonendothelial cells, NF-Y binds to
a noncanonical NF-Y binding site in this promoter to
repress transcription (62).
NF-Y has been reported to mediate repression and
several mechanisms appear to be utilized. In the case
of the growth hormone receptor promoter, NF-Y has
been shown to be part of a "repressosome" complex
that interacts with the co-repressor mSin3b (27). In
addition, NF-Y has been shown to interact with the
co-repressor, HDAC 1, in the regulation of at least
two promoters (63,75). The interaction of NF-Y with
either coactivators or co-repressors in response to different signals appears to parallel the bifunctional action of nuclear hormone receptors, which associate
with coactivators in the presence of hormone and activate transcription, but associate with co-repressors
in the absence of hormone and inhibit transcription
(65). Consequently, this prompted us to examine by
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ChIP analyses whether HDACI is associated with the
FGF-4 promoter in F9-differentiated cells. We were
unable to show enrichment of the FGF-4 promoter
with antibodies that recognize HDACl. However,
this negative result does not rule out the possibility
that HDACI or another co-repressor associates with
the FGF-4 promoter in differentiated EC cells. NFy may also function by influencing the binding of
transcription factors to neighboring cis-regulatory elements. In this regard, the binding of NF-Y to DNA
can induce bends of 60-80° in the DNA (46,72).
Thus, NF-Y could act as an architectural factor to
enhance transcription by increasing the affinity of
factors that bind to adjacent cis-regulatory elements,
as it does in the cases of Spl, SREBPl, and RF-X
binding to four different promoters. (33,67,71,84).
Similarly, NF-Y could to repress transcription by sterically blocking the binding of activating transcription factors to adjacent regulatory regions as it does
in the insulin gene and the renin gene (22,76).
Our studies demonstrate that the individual NF-Y
subunits are not sufficient to mediate repression of
the FGF-4 promoter, which suggests that multiple
subunits of NF-Y are required for repression. In this
regard, recruitment of a co-repressor may require a
binding surface that is formed by two or more of the
NF- Y subunits. For example, all three subunits of
NF- Y are required to interact with the stern! regulatory element binding protein, a transcription factor
involved in cholesterol and fatty acid metabolism
(20). Alternatively, repression by NF-Y may be a result of NF-Y binding to and bending DNA, thereby
altering the architecture of the promoter. For this reason, we examined the effect of altering the orientation and the position of the CCAAT box on its ability
to regulate the FGF-4 promoter. We show that the
CCAAT box can activate the FGF-4 promoter in either orientation in the presence of the FGF-4 enhancer, but it is unable to activate when it is moved
almost 200 bp upstream of its wild-type position. The
ability of the CCAAT box to activate transcription
regardless of orientation is not surprising considering
that CCAAT boxes are found throughout the genome
in either orientation, with roughly 60% of CCAAT
boxes being in the inverted ATTGG orientation (52).
The loss of function when the CCAAT box is moved
to an upstream position within the promoter may reflect the need for the CCAAT box to be within an

optimal distance of the TATA box. In promoters that
contain both a CCAAT box and a TATA box, the
CCAAT box is found most often between 80 and l 00
bp upstream of the transcription start site (52). In addition, NF-Y has been shown to interact with components of the basal transcriptional machinery (5,16,
26). Although changing the orientation of the CCAAT
box does not alter its function when the FGF-4 enhancer is active, this is not the case when the FGF-4
enhancer is absent. In the absence of the enhancer,
the CCAAT box fails to inhibit the FGF-4 promoter
if its orientation is reversed or if the CCAAT box is
moved to an upstream position. These results suggest
that the ability of NF-Y to repress the FGF-4 promoter is strictly dependent upon the orientation and
the position of the CCAAT box. Previous studies
have suggested that the CCAAT box and NF-Y may
play a structural role in gene regulation (46,52,72);
our findings provide direct evidence for an architectural role of NF-Yin the case of the FGF-4 promoter.
In conclusion, our studies provide evidence that
the CCAAT box of the FGF-4 promoter can activate
or repress transcription. We show that the FGF-4 enhancer, and more specifically p300, regulates the
function of the CCAAT box. Moreover, our findings
provide both functional and physical evidence that
NF-Y mediates the effect of the CCAAT box in both
F9 EC cells and F9-differentiated cells. Finally, we
demonstrate that orientation and position of the
CCAAT box are important and argue for an architectural role by the CCAAT box and NF-Y in the regulation of the FGF-4 promoter. Given these findings, the
system described in this study appears to provide an
excellent model for exploring the architectural role of
CCAAT boxes and for investigating the bifunctional
behavior of NF-Y and its regulation of genes that
play key roles during mammalian development.
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